Search results
Results From The WOW.Com Content Network
In December 2018, Dengvaxia was approved in the European Union. [7]In May 2019, Dengvaxia was approved in the United States as the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3, and 4) in people ages nine through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
The Dengvaxia controversy (locally [dɛŋˈvakʃa]) occurred in the Philippines when the dengue vaccine Dengvaxia was found to increase the risk of disease severity for some people who had received it. [1] [2] A vaccination program run by the Philippine Department of Health (DOH) administered Sanofi Pasteur's Dengvaxia to schoolchildren. [3]
Dengvaxia (formerly CYD-TDV) became available in 2015, and is approved for use in the US, EU and in some Asian and Latin American countries. [54] It is an attenuated virus, is suitable for individuals aged 6–45 years and protects against all four serotypes of dengue. [ 55 ]
The Japan-based company cited data collection issues, which cannot be addressed within the current review cycle. Sanofi's Dengvaxia, the world's first dengue vaccine, was licensed in 2015. Takeda ...
Dengue virus (DENV) is the cause of dengue fever.It is a mosquito-borne, single positive-stranded RNA virus of the family Flaviviridae; genus Flavivirus. [1] [2] Four serotypes of the virus have been found, and a reported fifth has yet to be confirmed, [3] [4] [5] all of which can cause the full spectrum of disease. [1]
This page was last edited on 14 November 2019, at 14:33 (UTC).; Text is available under the
A stringent regulatory authority is a regulatory authority which is: a) a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), being the European Commission, the US Food and Drug Administration and the Ministry of Health, Labour and Welfare of Japan also represented by the Pharmaceuticals and Medical Devices Agency (as before ...
Maybe "The Dengvaxia controversy contributed to overall vaccine hesitancy due to concern about vaccine safety in the Philippines. While some concerns about vaccine safety in the case of Dengvaxia were based on results from clinical trials, most concerns about vaccine safety are based on rumors rather than facts."